Cancer is the second leading cause of death globally, and is responsible for about 10 million deaths per year. With persistent and far-reaching unmet medical needs, oncology area shares rapidly rising market. Worldwide the pharmaceutical industry has never stopped its interests in marching new drugs or new therapies into this area.
HitGen is featured by its capability for one-stop new drug discovery. We have used new generation drug screening method such as DEL and FBDD to successfully identify hit compounds for targets of different categories. With DEL and FBDD platform, HitGen has advantages in identifying hits for novel or tough targets such as protein-protein interaction.
HitGen has applied its core technology and utilized its research platforms to fuel hit identification and lead optimization, hence have achieved differential competitiveness in peer group.
Building C2, NO.8, Huigu 1st East Road
Tianfu International Bio-Town,
Shuangliu District, Chengdu City,
Sichuan Province,P.R. China
Tel : +86-28-8519-7385
HitGen Pharmaceuticals Inc.(US Subsidiary)
Tel : +1-(508)-840-9646
Granta Park,Great Abington
Tel : +44(0)1223-895555